Miller Financial Services LLC Purchases New Stake in Cabaletta Bio, Inc. (NASDAQ:CABA)

Miller Financial Services LLC purchased a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,600 shares of the company’s stock, valued at approximately $33,000.

A number of other large investors also recently modified their holdings of CABA. Walleye Capital LLC raised its stake in shares of Cabaletta Bio by 111.6% in the 3rd quarter. Walleye Capital LLC now owns 401,982 shares of the company’s stock worth $1,897,000 after buying an additional 212,025 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Cabaletta Bio in the third quarter worth about $3,150,000. Geode Capital Management LLC increased its position in shares of Cabaletta Bio by 12.8% in the third quarter. Geode Capital Management LLC now owns 1,094,644 shares of the company’s stock worth $5,168,000 after acquiring an additional 124,071 shares in the last quarter. Barclays PLC raised its holdings in shares of Cabaletta Bio by 48.2% during the third quarter. Barclays PLC now owns 61,130 shares of the company’s stock valued at $288,000 after acquiring an additional 19,891 shares during the period. Finally, XTX Topco Ltd lifted its position in shares of Cabaletta Bio by 490.2% in the 3rd quarter. XTX Topco Ltd now owns 87,455 shares of the company’s stock valued at $413,000 after acquiring an additional 72,638 shares in the last quarter.

Cabaletta Bio Trading Up 1.1 %

CABA stock opened at $1.79 on Wednesday. The firm has a market cap of $87.49 million, a PE ratio of -0.83 and a beta of 2.58. Cabaletta Bio, Inc. has a 1 year low of $1.59 and a 1 year high of $21.24. The company has a fifty day simple moving average of $2.28 and a 200 day simple moving average of $3.28.

Analyst Upgrades and Downgrades

CABA has been the subject of several research analyst reports. Evercore ISI downgraded Cabaletta Bio from an “outperform” rating to an “inline” rating and reduced their price objective for the stock from $15.00 to $6.00 in a research note on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Cabaletta Bio in a research report on Tuesday, February 18th. William Blair reiterated an “outperform” rating on shares of Cabaletta Bio in a research report on Monday, November 18th. Wells Fargo & Company cut shares of Cabaletta Bio from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $12.00 to $6.00 in a report on Thursday, December 19th. Finally, TD Cowen upgraded Cabaletta Bio to a “strong-buy” rating in a report on Friday, November 29th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $22.71.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.